Related Experiment Videos
Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus
Patrick G P Charles1, Peter B Ward, Paul D R Johnson
1Department of Infectious Diseases, Austin Health, Heidelberg, Victoria, Australia. patrick.charles@mh.org.au
Summary
Heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) bacteremia is linked to higher bacterial loads and treatment failure. Early identification of these methicillin-resistant Staphylococcus aureus (MRSA) infections can improve patient outcomes.
Area of Science:
- Infectious Diseases
- Clinical Microbiology
- Pharmacology
Background:
- Methicillin-resistant Staphylococcus aureus (MRSA) bacteremia poses a significant clinical challenge.
- Vancomycin remains a primary treatment, but reduced susceptibility, including heterogeneous vancomycin-intermediate S. aureus (hVISA), complicates therapy.
- Understanding hVISA epidemiology and clinical presentation is crucial for effective management.
Purpose of the Study:
- To compare clinical characteristics and outcomes of hVISA bacteremia versus vancomycin-susceptible MRSA bacteremia.
- To identify potential clinical markers associated with hVISA infections.
Main Methods:
- Retrospective analysis of all MRSA bacteremia cases over a 12-month period.
- Comparison of patients with hVISA isolates (n=5) against those with vancomycin-susceptible MRSA isolates (n=48).
- Assessment of bacterial load, treatment duration, and serum vancomycin levels.
Main Results:
- Patients with hVISA bacteremia were more likely to present with high bacterial loads (P=.001).
- Treatment failure, defined as persistent fever and bacteremia for >7 days, was significantly higher in the hVISA group (P<.001).
- hVISA cases were associated with initially low serum vancomycin levels (P=.006).
Conclusions:
- hVISA bacteremia is associated with increased risk of treatment failure and higher bacterial burden.
- Clinical indicators such as high bacterial load and low initial vancomycin levels may suggest hVISA.
- These findings can guide focused diagnostic and therapeutic strategies for MRSA bacteremia.